- Home
- AKBA vs PZZA Comparison
AKBA vs PZZA Comparison
Compare AKBA & PZZA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- PZZA
- Stock Information
- Founded
- AKBA 2007
- PZZA 1984
- Country
- AKBA United States
- PZZA United States
- Employees
- AKBA N/A
- PZZA N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- PZZA Restaurants
- Sector
- AKBA Health Care
- PZZA Consumer Discretionary
- Exchange
- AKBA Nasdaq
- PZZA Nasdaq
- Market Cap
- AKBA 958.6M
- PZZA 1.1B
- IPO Year
- AKBA 2014
- PZZA 1993
- Fundamental
- Price
- AKBA $3.97
- PZZA $47.93
- Analyst Decision
- AKBA Strong Buy
- PZZA Buy
- Analyst Count
- AKBA 5
- PZZA 12
- Target Price
- AKBA $6.90
- PZZA $51.36
- AVG Volume (30 Days)
- AKBA 5.0M
- PZZA 1.4M
- Earning Date
- AKBA 08-07-2025
- PZZA 08-07-2025
- Dividend Yield
- AKBA N/A
- PZZA 3.82%
- EPS Growth
- AKBA N/A
- PZZA 4.47
- EPS
- AKBA N/A
- PZZA 2.37
- Revenue
- AKBA $184,909,000.00
- PZZA $2,063,780,000.00
- Revenue This Year
- AKBA $26.88
- PZZA $4.30
- Revenue Next Year
- AKBA $44.34
- PZZA $3.68
- P/E Ratio
- AKBA N/A
- PZZA $20.35
- Revenue Growth
- AKBA N/A
- PZZA N/A
- 52 Week Low
- AKBA $0.93
- PZZA $30.16
- 52 Week High
- AKBA $4.08
- PZZA $60.75
- Technical
- Relative Strength Index (RSI)
- AKBA 62.71
- PZZA 51.90
- Support Level
- AKBA $3.48
- PZZA $46.51
- Resistance Level
- AKBA $3.77
- PZZA $51.63
- Average True Range (ATR)
- AKBA 0.17
- PZZA 1.77
- MACD
- AKBA -0.04
- PZZA -0.51
- Stochastic Oscillator
- AKBA 62.82
- PZZA 27.73
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About PZZA Papa John's International Inc.
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.